AdaptHealth Corp. Director Departs, New Director Appointed
Ticker: AHCO · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1725255
Sentiment: neutral
Topics: board-change, executive-compensation
TL;DR
AdaptHealth's board sees a change: Dr. Smith out, Dr. McNeely in. Exec comp details pending.
AI Summary
AdaptHealth Corp. announced on December 9, 2024, the departure of director Dr. David M. Smith and the appointment of Dr. Michael J. McNeely as a new director. Additionally, the company reported on compensatory arrangements for its named executive officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on executive compensation are crucial for understanding management incentives.
Risk Assessment
Risk Level: low — This filing primarily reports routine board changes and mentions executive compensation without detailing specific financial impacts or new agreements.
Key Players & Entities
- AdaptHealth Corp. (company) — Registrant
- Dr. David M. Smith (person) — Departing Director
- Dr. Michael J. McNeely (person) — Appointed Director
- December 9, 2024 (date) — Date of earliest event reported
FAQ
Who is the departing director and when did their departure become effective?
Dr. David M. Smith departed as a director, with the earliest event reported on December 9, 2024.
Who is the newly appointed director?
Dr. Michael J. McNeely was appointed as a new director.
What is the company's primary business?
AdaptHealth Corp. is in the Home Health Care Services industry.
What is the filing date of this Form 8-K?
This Form 8-K was filed on December 13, 2024.
What other item information is reported in this filing besides director changes?
The filing also reports on the election of directors and compensatory arrangements of certain officers, as well as financial statements and exhibits.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-12-13 11:07:34
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share AHCO The Nasdaq Stock Mar
- $500,000 — d to reduce his annual base salary from $500,000 to $125,000 commencing on January 1, 20
- $125,000 — his annual base salary from $500,000 to $125,000 commencing on January 1, 2025. The fore
Filing Documents
- tm2430799d1_8k.htm (8-K) — 28KB
- tm2430799d1_ex10-1.htm (EX-10.1) — 7KB
- 0001104659-24-128292.txt ( ) — 207KB
- ahco-20241209.xsd (EX-101.SCH) — 3KB
- ahco-20241209_lab.xml (EX-101.LAB) — 33KB
- ahco-20241209_pre.xml (EX-101.PRE) — 22KB
- tm2430799d1_8k_htm.xml (XML) — 4KB
02. Departure of Directors or Certain
Item 5.02. Departure of Directors or Certain Officers Election of Directors Appointment of Certain Officers Compensatory Arrangements of Certain Officers. Amendment to Rietkerk Transition, Separation and Release Agreement On December 9, 2024, AdaptHealth Corp. (the "Company") entered into an amendment (the "Rietkerk Amendment") to its transition, separation, and release agreement with Shaw Rietkerk, the Company's Chief Business Officer, dated August 21, 2024, pursuant to which Mr. Rietkerk agreed to reduce his annual base salary from $500,000 to $125,000 commencing on January 1, 2025. The foregoing description of the Rietkerk Amendment is qualified in its entirety by reference to the full text of the Rietkerk Amendment, which is attached as Exhibit 10.1 hereto and incorporated by reference herein.
01 Financial
Item 9.01 Financial (d) Exhibits Exhibit No. Description 10.1 Amendment to Transition, Separation and Release Agreement between AdaptHealth Corp. and Shaw Rietkerk, dated December 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) - 2 - SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: December 13, 2024 AdaptHealth Corp. By: /s/ Jason Clemens Name: Jason Clemens Title: Chief Financial Officer - 3 -